CAJ | 학술논문

目的：系统评价吡格列酮联合二甲双胍治疗2型糖尿病的疗效和安全性。方法：检索Cochrane Library、PubMed、EMbase、CBM、CNKI、VIP、WanFang Data共7个数据库，收集主题为吡格列酮联合二甲双胍治疗2型糖尿病的文献；根据排除标准筛选确定最终文献，并根据Cochrane手册评价纳入研究质量，最后提取结局指标数据运用RevMan 5.2进行meta分析。结果：纳入15篇文献，包含T2DM患者1881例，其中联合组941例，二甲双胍单用组940例。结果显示，联合组更能有效降低血糖和糖化血红蛋白，改善胰岛素及血脂，但体质指数无显著差异；不良反应方面，两组在胃肠道事件发生率方面无显著差异；但联合组的水肿发生率略高于单用组。结论：联合用药效果优于二甲双胍单用，且安全性良好。
목적：계통평개필격렬동연합이갑쌍고치료2형당뇨병적료효화안전성。방법：검색Cochrane Library、PubMed、EMbase、CBM、CNKI、VIP、WanFang Data공7개수거고，수집주제위필격렬동연합이갑쌍고치료2형당뇨병적문헌；근거배제표준사선학정최종문헌，병근거Cochrane수책평개납입연구질량，최후제취결국지표수거운용RevMan 5.2진행meta분석。결과：납입15편문헌，포함T2DM환자1881례，기중연합조941례，이갑쌍고단용조940례。결과현시，연합조경능유효강저혈당화당화혈홍단백，개선이도소급혈지，단체질지수무현저차이；불량반응방면，량조재위장도사건발생솔방면무현저차이；단연합조적수종발생솔략고우단용조。결론：연합용약효과우우이갑쌍고단용，차안전성량호。
Objective: The effectiveness and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes mellitus (T2DM) were systematically reviewed. Methods:The related literatures were searched and collected from 7 databases including Cochrane Library, PubMed, EMbase, CBM, CNKI, VIP, WanFang Data. The ifnal literatures were selected based on inclusion and exclusion criteria. Their quality was evaluated according to the Cochrane Collaboration’s tool for assessing risk of bias in randomized controlled trials and the data were measured using RevMan 5.2 software. Results:Fifteen studies were included involving in a total of 1 881 cases with T2DM (941 cases in combination therapy group and 940 in metformin mono-therapy group). Meta-analysis results showed that the levels for blood glucose, HbA1c, insulin and HDL-C were more effectively improved in the combination therapy group, however, there were no signiifcant differences in BMI as well as the incidence of gastrointestinal events. The incidence of edema is a little bit higher in combination therapy group than in mono-therapy group. Conclusion:The combination therapy of pioglitazone and metformin showed a better efifciency and was well tolerated.